TY - JOUR
T1 - Myelin oligodendrocyte glycoprotein antibody-associated disorders coexisting with ankylosing spondylitis
T2 - Potential association between demyelination and tumor necrosis factor inhibitors
AU - Luo, Wenjng
AU - Li, Rui
AU - Chang, Yanyu
AU - She, Hongda
AU - Kermode, Allan G.
AU - Qiu, Wei
PY - 2021/6
Y1 - 2021/6
N2 - Myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD) is a newly described demyelinating disease. Ankylosing spondylitis (AS) is an inflammatory disease that predominantly affects the axial skeleton. Treatments for AS, such as tumor necrosis factor alpha (TNFα) inhibitors, may induce demyelination. We report the first case of MOGAD coexisting with AS and postulate a potential association with TNFα inhibitors. Further studies are needed to clarify the risk of demyelinating events following anti-TNFα therapy and to elucidate the relationship between MOGAD and AS.
AB - Myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD) is a newly described demyelinating disease. Ankylosing spondylitis (AS) is an inflammatory disease that predominantly affects the axial skeleton. Treatments for AS, such as tumor necrosis factor alpha (TNFα) inhibitors, may induce demyelination. We report the first case of MOGAD coexisting with AS and postulate a potential association with TNFα inhibitors. Further studies are needed to clarify the risk of demyelinating events following anti-TNFα therapy and to elucidate the relationship between MOGAD and AS.
UR - http://www.scopus.com/inward/record.url?scp=85102812220&partnerID=8YFLogxK
U2 - 10.1016/j.msard.2021.102889
DO - 10.1016/j.msard.2021.102889
M3 - Letter
C2 - 33756439
AN - SCOPUS:85102812220
SN - 2211-0348
VL - 51
JO - Multiple Sclerosis and Related Disorders
JF - Multiple Sclerosis and Related Disorders
M1 - 102889
ER -